A Phase 1/2 interventional study of Mifepristone and Placebo - Cap in Alcohol Use Disorder, sponsored by Johns Hopkins University. Completed at 1 site in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-30.
Sponsored by Johns Hopkins University · Phase 1/2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Alcoholism by Johns Hopkins University — 7 open to participants now, 8 under way, 1 of them phase 3. Alcoholism · Johns Hopkins University.
Among the 15 studies in Alcoholism by Johns Hopkins University, this one is the 13th largest by enrollment, is the only one that started in 2017, is the only one in phase 1/2, and was the 7th registered.
1,677 studies on the registry are indexed under Alcoholism; 332 are open to participants now.
Browse Alcoholism studies →7 of the 15 studies in Alcoholism by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 21–65
Johns Hopkins University · Sites in United States
Ages 25–55 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 239 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 132 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 21 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 1 · Phase 4 1
First in 2001; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is below the median of 88 across 1,431 interventional studies indexed under Alcoholism.
Median enrollment 122 across the 15 interventional studies. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
3 of the studies in Alcoholism by Johns Hopkins University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05163301Johns Hopkins UniversityAlcohol Research in HIV: Relapse Prevention | 2027-02-25 |
| NCT05732207Johns Hopkins UniversityCerebellar Involvement in Alcohol Use Disorder (AUD) | 2027-04 |
| NCT03845205Johns Hopkins UniversityAlcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Alcoholism by Johns Hopkins University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In alcohol use disorder (AUD) and matched healthy control (HC) men and women, the proposed research examines the effects of MIFE, with demonstrated preclinical effects on drinking-related behaviors, compared with placebo on a breadth of alcohol-related measures. All subjects will be randomized to daily MIFE or placebo. Before and during medication, AUD and HC subjects undergo fMRI scanning measuring resting-state functional connectivity and alcohol cue-induced brain activation focused on brain reward and stress pathways. All subjects are admitted to the Clinical Research Unit; AUD subjects undergo supervised alcohol withdrawal with daily measurements of alcohol craving and symptom severity. Using validated human laboratory procedures in AUD subjects, this study will examine the effects of stress on motivation to drink and alcohol sensitivity/reward as a function of GR antagonism.
Cortisol (CORT) is a glucocorticoid hormone, often associated with response to stress and playing a key role in alcohol use and problems. First, acute alcohol administration increases CORT, which in turn amplifies the mesolimbic dopamine reward signal. Second, alcohol withdrawal elevates CORT levels in AUD compared with healthy control subjects, and CORT levels in early abstinence predict subsequent relapse to drinking. Finally, the magnitude of CORT response to external stressors predicts motivation to work for and consumption of alcohol in the human laboratory and in the natural environment. Importantly, recent studies in rodents and humans have demonstrated that blocking CORT activity using a glucocorticoid receptor (GR) antagonist reduces these effects of CORT on alcohol behaviors, indicating a causal role for glucocorticoids in these relationships. In alcohol use disorder (AUD) and matched healthy control (HC) men and women, the proposed research examines the effects of MIFE, with demonstrated preclinical effects on drinking-related behaviors, compared to placebo on a breadth of alcohol-related measures. All subjects will be randomized to daily MIFE or placebo. Before and during medication, AUD and HC subjects undergo fMRI scanning measuring resting-state functional connectivity and alcohol cue-induced brain activation focused on brain reward and stress pathways. All subjects are admitted to the Clinical Research Unit; AUD subjects undergo supervised alcohol withdrawal with daily measurements of alcohol craving and symptom severity. Using validated human laboratory procedures in AUD subjects, this study will examine the effects of stress on motivation to drink and alcohol sensitivity/reward as a function of GR antagonism. This work will help pave the way for improved pharmacotherapies that target stress and reward pathways in the brain involved in initiating and maintaining drinking.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants diagnosed with alcohol use disorder who were randomized to receive mifepristone. Mifepristone is a high affinity antagonist of the glucocorticoid receptor (GR). It is FDA approved to treatment hyperglycemia caused by high cortisol levels in adults with endogenous Cushing's syndrome.
Drug: Mifepristone
Participants diagnosed with alcohol use disorder who were randomized to receive placebo. This is an inactive compound which appears physically identical to active medication.
Drug: Placebo - Cap
Healthy control participants who were randomized to receive mifepristone. Mifepristone is a high affinity antagonist of the glucocorticoid receptor (GR). It is FDA approved to treatment hyperglycemia caused by high cortisol levels in adults with endogenous Cushing's syndrome.
Drug: Mifepristone
Healthy control participants who were randomized to receive placebo. This is an inactive compound which appears physically identical to active medication.
Drug: Placebo - Cap
Participants receive 6 doses.
Also known as: Korlym
Participants receive 6 doses
Change in Blood Oxygen Level Dependent (BOLD) fMRI Signal for Alcohol Versus Non-alcohol Stimuli
Participants observed alcohol and neutral cues during functional MRI (fMRI) scans. Larger numbers indicate greater activation to alcohol versus non alcohol stimuli. Mean response Pre and Post medication (mifepristone (MIFE), placebo), is measured. The greater the number the greater the reactivity to alcohol-related cues.
Time frame: Change from baseline (Day 1) to day 4 of MIFE dosing
Mean of Alcohol Motivated Responses Made
Participants made alcohol motivated responses with a computer mouse to earn either alcohol drinks or money. Each mouse click equaled one response. Mean of all responses made are reported.
Time frame: single session on study day 5
Alcohol Motivated Responding - Number of Drinks Earned
Participants can earn up to 10 drinks during a 1-hr session. Each drink was the equivalent of 0.5 standard drink.
Time frame: single session on study day 5
| Milestone | Alcohol Use Disorder - Mifepristone | Alcohol Use Disorder - Placebo | Healthy Control - Mifepristone | Healthy Control - Placebo |
|---|---|---|---|---|
| Started | 4 | 3 | 6 | 3 |
| Completed | 0 | 3 | 6 | 1 |
| Not completed | 4 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 |
| Withdrew: Physician decision | 3 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
Participants observed alcohol and neutral cues during functional MRI (fMRI) scans. Larger numbers indicate greater activation to alcohol versus non alcohol stimuli. Mean response Pre and Post medication (mifepristone (MIFE), placebo), is measured. The greater the number the greater the reactivity to alcohol-related cues.
| BOLD response | Alcohol Use Disorder - Mifepristone | Alcohol Use Disorder - Placebo | Healthy Control - Mifepristone | Healthy Control - Placebo |
|---|---|---|---|---|
| Amygdala, centromedian - day 1 | — | 0.267390 ± 0.128827 | 0.040281 ± 0.074378 | 0.058670 ± 0.128827 |
| Amygdala, centromedian - day 4 | — | -0.069048 ± 0.142952 | 0.037178 ± 0.082533 | 0.052388 ± 0.142952 |
| Amygdala, lateral - day 1 | — | 0.091174 ± 0.190861 | 0.151864 ± 0.110194 | 0.099169 ± 0.190861 |
| Amygdala, lateral - day 4 | — | 0.294417 ± 0.115607 | -0.021411 ± 0.066746 | 0.126445 ± 0.115607 |
| medial prefrontal cortex - day 1 | — | 0.044635 ± 0.287281 | -0.323039 ± 0.165862 | 0.031454 ± 0.287281 |
| medial prefrontal cortex - day 4 | — | 0.439822 ± 0.226576 | 0.257514 ± 0.130814 | -0.514729 ± 0.226576 |
| nucleus accumbens - day 1 | — | 0.138441 ± 0.147427 | 0.131360 ± 0.085117 | 0.262425 ± 0.147427 |
| nucleus accumbens - day 4 | — | 0.285409 ± 0.106153 | 0.138914 ± 0.061287 | -0.003538 ± 0.106153 |
| Amygdala, superficial - day 1 | — | 0.583073 ± 0.269851 | 0.252555 ± 0.155799 | -0.111622 ± 0.269851 |
| Amygdala, superficial - day 4 | — | 0.149175 ± 0.347008 | 0.172212 ± 0.200345 | 0.118748 ± 0.347008 |
| ventral tegmental area - day 1 | — | 0.405165 ± 0.227379 | 0.566876 ± 0.131277 | -0.019192 ± 0.227379 |
| ventral tegmental area - day 4 | — | 0.430387 ± 0.176868 | -0.150802 ± 0.102115 | 0.104408 ± 0.176868 |
Participants made alcohol motivated responses with a computer mouse to earn either alcohol drinks or money. Each mouse click equaled one response. Mean of all responses made are reported.
| responses made | Alcohol Use Disorder - Mifepristone | Alcohol Use Disorder - Placebo | Healthy Control - Mifepristone | Healthy Control - Placebo |
|---|---|---|---|---|
| Mean of Alcohol Motivated Responses Made | — | 9517 ± 1497.6 | — | — |
Participants can earn up to 10 drinks during a 1-hr session. Each drink was the equivalent of 0.5 standard drink.
| drinks earned | Alcohol Use Disorder - Mifepristone | Alcohol Use Disorder - Placebo | Healthy Control - Mifepristone | Healthy Control - Placebo |
|---|---|---|---|---|
| Alcohol Motivated Responding - Number of Drinks Earned | — | 7 ± 3 | — | — |
Collected over Up to 6 weeks post followup. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alcohol Use Disorder - Mifepristone | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Alcohol Use Disorder - Placebo | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Healthy Control - Mifepristone | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Health Control - Placebo | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Event | Alcohol Use Disorder - Mifepristone | Alcohol Use Disorder - Placebo | Healthy Control - Mifepristone | Health Control - Placebo |
|---|---|---|---|---|
| RashSkin and subcutaneous tissue disorders | 0/4 | 0/3 | 2/6 | 0/3 |
| Age, Continuous(years) | Alcohol Use Disorder - Mifepristone | Alcohol Use Disorder - Placebo | Healthy Control - Mifepristone | Healthy Control - Placebo | Total |
|---|---|---|---|---|---|
| Mean | 42.3 ± 11.8 | 41.3 ± 7.1 | 38.3 ± 13.8 | 33.7 ± 8.6 | 39.1 ± 11.5 |
| Sex: Female, Male(Participants) | Alcohol Use Disorder - Mifepristone | Alcohol Use Disorder - Placebo | Healthy Control - Mifepristone | Healthy Control - Placebo | Total |
|---|---|---|---|---|---|
| Female | 1 | 2 | 1 | 0 | 4 |
| Male | 3 | 1 | 5 | 3 | 12 |
| Race (NIH/OMB)(Participants) | Alcohol Use Disorder - Mifepristone | Alcohol Use Disorder - Placebo | Healthy Control - Mifepristone | Healthy Control - Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 2 | 2 | 8 |
| White | 1 | 1 | 3 | 1 | 6 |
| More than one race | 0 | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Alcohol Use Disorder - Mifepristone | Alcohol Use Disorder - Placebo | Healthy Control - Mifepristone | Healthy Control - Placebo | Total |
|---|---|---|---|---|---|
| United States | 4 | 3 | 6 | 3 | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2017 to primary completion in Jan 2024, 76 months.
Results were first posted in May 2025, 1 year 3 months after primary completion.
Of 22 phase 1/2 interventional studies under Alcoholism, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 76. This study's 76 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mifepristone